There is growing recognition that B cell contributions to normal immune responses extend
well beyond their potential to become antibody-producing cells, including roles at the innate …

Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …

The origin and function of CD20+ T cells are poorly understood. Here, we characterized
CD20+ T cells in mice and humans and investigated how they are affected by anti-CD20 …

A small proportion of multiple sclerosis (MS) patients develop new disease activity soon after
starting anti-CD20 therapy. This activity does not recur with further dosing, possibly reflecting …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS) that is characterised pathologically by demyelination, gliosis, neuro-axonal damage …

Monoclonal Abs against CD20 reduce the number of relapses in multiple sclerosis (MS);
commonly this effect is solely attributed to depletion of B cells. Recently, however, a subset …

In multiple sclerosis (MS), B cell–depleting therapy using monoclonal anti-CD20 Abs,
including rituximab (RTX) and ocrelizumab, effectively reduces disease activity. Based on …

Background: Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic
nerves and spinal cord. The monoclonal anti-CD20 B-cell antibody rituximab is an emerging …

Ocrelizumab, a humanized monoclonal anti-CD20 antibody, has shown pronounced effects
in reduction of disease activity in multiple sclerosis (MS) patients and has recently been …

With the discovery that the highly effective anti-CD20 antibody therapies developed to
deplete CD20+ B cells deplete CD20+ T cells equally well, a great interest in the biological …